In primary membranous nephropathy, obinutuzumab increased the likelihood of complete remission vs. tacrolimus at 104 wk.
Medicine
Abstract
CLINICAL IMPACT RATINGS GIM/FP/GP: [Formula: see text] Nephrology: [Formula: see text].